Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty


Contact us for more batch information
Select Batch
Resource Download


Catalog No. T4496Cas No. 342777-54-2
LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor and can induce TrkB, TrkC, ERK and AKT activation in vitro and in vivo.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
1 mg$54In Stock
2 mg$84In Stock
5 mg$128In Stock
10 mg$216In Stock
25 mg$497In Stock
50 mg$747In Stock
100 mg$1,050In Stock
1 mL x 10 mM (in DMSO)$135In Stock
Bulk & Custom
Add to Cart
View More

Related Compound Libraries of "LM22B-10"

Product Introduction

LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor and can induce TrkB, TrkC, ERK and AKT activation in vitro and in vivo.
In vitro
LM22B-10 exhibits superior neurotrophic activity, surpassing the highest levels of neurotrophic survival activity achieved by BDNF (53 ± 7.2% above BDNF at 0.7 nM) and NT-3 (91 ± 8.6% above NT-3 at 0.7 nM), with an EC50 value between 200-300 nM. At a concentration of 1000 nM, LM22B-10 significantly increases neurite length, achieving an average increment up to -40 μM. Furthermore, LM22B-10 demonstrates dose-dependent binding to TrkB-Fc and TrkC-Fc across a concentration range of 250-2000 nM. It effectively inhibits the binding of BDNF to TrkB-expressing cells and NT-3 to TrkC-expressing cells, supporting cell survival and preferentially engaging TrkB and TrkC pathways. Notably, LM22B-10 promotes neurite outgrowth even in inhibitory conditions, a capability not displayed by BDNF or NT-3. It triggers distinct Trk and subsequent signaling activation patterns, as well as stimulating TrkB, TrkC, AKT, and ERK activation in cultured hippocampal neurons, establishing its unique and potent neurotrophic effects compared to those of BDNF and NT-3[1].
In vivo
LM22B-10, at a dosage of 0.5 mg/kg, stimulates TrkB, TrkC, AKT, and ERK pathways in C57BL/6J mice. At a higher concentration of 50 mg/kg administered intraperitoneally (i.p.), it induces enhanced phosphorylation at TrkBY817 and TrkCY820. Furthermore, LM22B-10 triggers synaptic activation of TrkB and TrkC, elevating both pre- and post-synaptic protein levels and augmenting spine density in elderly mice [1].
Cell Research
Mouse NIH-3T3 cells, mouse NIH-3T3 cells expressing TrkA (NIH-3T3-TrkA) or p75NTR (NIH-3T3-p75NTR), and NIH-3T3 cells expressing TrkB (NIH-3T3-TrkB) or TrkC (NIH-3T3-TrkC) are propagated in DMEM supplemented with 10% FBS and 200-400 μg/mL Geneticin (for Trk-expressing cells) or 400 μg/mL hygromycin (for p75NTR-expressing cells). Cells are seeded into 24-well plates (30,000 cells/well) and cultured in medium consisting of 50% PBS and 50% DMEM without supplements. Following exposure to growth factors (0.7 nM) or 1000 nM LM22B-10 for 72-96 h, cells are suspended in 50 μL lysis buffer, transferred to opaque 96-well culture plates and survival is measured using the ViaLight Assay.
Chemical Properties
Molecular Weight485.01
Cas No.342777-54-2
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
Ethanol: 4.5 mg/mL
DMSO: 50 mg/mL (103.09 mM)
Solution Preparation Table
1 mM2.0618 mL10.3091 mL20.6181 mL103.0907 mL
5 mM0.4124 mL2.0618 mL4.1236 mL20.6181 mL
10 mM0.2062 mL1.0309 mL2.0618 mL10.3091 mL
20 mM0.1031 mL0.5155 mL1.0309 mL5.1545 mL
50 mM0.0412 mL0.2062 mL0.4124 mL2.0618 mL
100 mM0.0206 mL0.1031 mL0.2062 mL1.0309 mL


  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg,each TargetMol | Animal experiments animal weighs 20 g, and the dosage volume is 100 μL. A total of TargetMol | Animal experiments 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL.
Mother liquor preparation method: 2 mg of drug dissolved in 50 μLDMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μLDMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μLTween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify.
1 Enter information below:
2 Enter the in vivo formulation:
%Tween 80

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.